Eirin et al., 2013 - Google Patents
Inflammatory and injury signals released from the post-stenotic human kidneyEirin et al., 2013
View HTML- Document ID
- 16948332703776067873
- Author
- Eirin A
- Gloviczki M
- Tang H
- Gössl M
- Jordan K
- Woollard J
- Lerman A
- Grande J
- Textor S
- Lerman L
- Publication year
- Publication venue
- European heart journal
External Links
Snippet
Aims The mechanisms mediating kidney injury and repair in humans with atherosclerotic renal artery stenosis (ARAS) remain poorly understood. We hypothesized that the stenotic kidney releases inflammatory mediators and recruits progenitor cells to promote …
- 210000003734 Kidney 0 title abstract description 79
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eirin et al. | Inflammatory and injury signals released from the post-stenotic human kidney | |
| Bernelot Moens et al. | PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia | |
| Langheim et al. | Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome | |
| Baldini et al. | The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms | |
| Lin et al. | Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases | |
| Davidson | What is damaging the kidney in lupus nephritis? | |
| Campion et al. | Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy | |
| Kleveland et al. | Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial | |
| Kohno et al. | Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling | |
| Crowley et al. | Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension | |
| Ridker et al. | Anti-inflammatory therapies for cardiovascular disease | |
| Noronha et al. | The inflammatory component in progressive renal disease—are interventions possible? | |
| Ueland et al. | Soluble CD40 ligand in acute and chronic heart failure | |
| Derhaschnig et al. | Increased levels of transforming growth factor-β1 in essential hypertension | |
| Liu et al. | Innate immune cells in pressure overload-induced cardiac hypertrophy and remodeling | |
| Crowley et al. | A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II–dependent hypertension | |
| Eirin et al. | Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis | |
| Satirapoj et al. | Novel insights into the relationship between glomerular pathology and progressive kidney disease | |
| Yada et al. | Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6Clo macrophages | |
| Mehta et al. | IL-6 and cardiovascular risk: A narrative review | |
| Bamias et al. | Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis | |
| Flammer et al. | Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers | |
| Shi et al. | LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis | |
| Ruiz‐Ortega et al. | ACE inhibitors and AT1 receptor antagonists—beyond the haemodynamic effect | |
| Hess et al. | Vascular repair and regeneration in cardiometabolic diseases |